Research Finds 10%-30% of GLP-1 Patients Fail to Lose Weight as Genes and Habits Interfere
Updated
Updated · The Conversation · Jun 17
Research Finds 10%-30% of GLP-1 Patients Fail to Lose Weight as Genes and Habits Interfere
3 articles · Updated · The Conversation · Jun 17
Summary
10%-30% of GLP-1 users are "non-responders," losing less than 5% of body weight after about six months even on the highest tolerated dose.
Research points to several drivers: early discontinuation, underdosing, insulin resistance, poor sleep, and weight-gain drugs such as corticosteroids or antidepressants can all blunt semaglutide's effect.
Genetics may also matter—about 10% of people carry PAM variants linked to GLP-1 resistance, while studies of nearly 28,000 users found GLP-1R and GIPR differences tied to weaker weight loss and more side effects.
Response also varies by patient profile and eating pattern: a review of 47 trials covering 23,000 patients found younger women without diabetes lost the most weight, while emotional eaters may need cognitive behavioral therapy alongside medication.
The findings bolster a push toward precision obesity treatment, matching drugs, diet, exercise and behavioral support to each patient's genes, metabolism and main driver of overeating.